Lantheus Holdings, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Amounts below are in U.S. dollars; financial statement amounts are rounded to millions unless stated otherwise.
Business context
Lantheus develops and commercializes radiopharmaceuticals, diagnostic imaging products, and related digital and partnership offerings. Its largest growth driver was PYLARIFY, a prostate cancer imaging agent. The company operates as one business segment.
Key financial results
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $319.9 million | $239.3 million | $942.4 million | $671.9 million |
| Gross profit | $200.0 million | $147.4 million | $479.7 million | $414.5 million |
| Gross margin | 62.5% | 61.6% | 50.9% | 61.7% |
| Operating income | $112.4 million | $85.7 million | $227.2 million | $207.9 million |
| Net income | $132.0 million | $61.2 million | $223.3 million | $147.3 million |
| Diluted EPS | $1.88 | $0.86 | $3.18 | $2.08 |
| Cash provided by operating activities | — | $193.0 million | $176.4 million |
Q3 revenue rose 33.7% year over year, led by PYLARIFY, whose sales increased 49.9% to $215.4 million. DEFINITY revenue increased 10.9% to $67.3 million. Nine-month revenue grew 40.3%, with PYLARIFY up 69.4% and DEFINITY up 14.0%.
Q3 net income included a $51.8 million gain from selling the RELISTOR royalty asset and benefited from lower contingent consideration liabilities. Nine-month gross margin fell to 50.9%, principally reflecting a $116.4 million AZEDRA marketed-product impairment and other impairment charges, including $15.6 million for an AZEDRA in-process research and development asset and $6.0 million for property and equipment. These items make the nine-month earnings comparison less representative of underlying operating trends.
Balance sheet, liquidity and debt
- Cash and cash equivalents were $614.1 million at September 30, 2023, versus $415.7 million at December 31, 2022.
- Total assets were $1.522 billion and total liabilities were $822.9 million. Current assets of $948.4 million exceeded current liabilities of $176.6 million.
- Principal outstanding on the 2.625% convertible notes was $575.0 million, due December 2027. The notes are senior unsecured obligations. No borrowings were outstanding under the $350 million revolving credit facility.
- Operating cash flow was $193.0 million. Investing activities provided $18.0 million, largely from the RELISTOR asset sale, offset by Cerveau acquisition spending and capital expenditures. Financing activities used $12.6 million.
- Management said cash, operating cash generation, and continued access to the revolver were expected to cover requirements over the next twelve months and beyond. The company reported compliance with its credit covenants at quarter-end.
Material changes and notable items
- RELISTOR: Lantheus sold its rights to net-sales royalties in August for an initial payment of approximately $98 million, recognizing a $51.8 million gain. It retained rights to a potential $5 million milestone payment if a specified 2025 sales threshold is met, but no longer receives the sold royalties.
- AZEDRA: The company decided to discontinue production and promotion and wind down its Somerset, New Jersey site. It intended, where feasible, to continue manufacturing into Q1 2024 to support patients completing treatment.
- CVRs: The company paid $99.6 million in May 2023, satisfying the PYLARIFY-related contingent value rights obligation in full.
- Cerveau: The company acquired MK-6240, an investigational Alzheimer’s tau imaging agent, for approximately $45.3 million in upfront and technology-transfer payments. Additional regulatory, sales and research milestones and royalties may be payable.
Outlook, commentary and risks
The filing provides no quantified company-wide revenue or earnings guidance. Management expected topline results from the PNT2002 SPLASH Phase 3 trial in Q4 2023 and expected to open an expanded access program for PNT2002 in that quarter. The FDA granted Fast Track designation to PNT2002 and MK-6240. These are forward-looking expectations, not reported outcomes.
Management emphasized PYLARIFY’s growth opportunity but noted increasing competition, reimbursement uncertainty, and dependence on third-party manufacturing and supply. In particular, Mo-99 disruptions could constrain TechneLite supply; DEFINITY also relies substantially on external suppliers. Other risks include clinical and regulatory uncertainty for pipeline products, substantial potential milestone and royalty obligations, cost pressures, and the ability to maintain credit covenant compliance if borrowings increase. The company reported no material ongoing litigation and no material changes to the risk factors in its 2022 Form 10-K.
Important facts for investors to verify
- How much of reported earnings growth reflects recurring product operations versus the RELISTOR gain and contingent-liability fair-value changes.
- The effect of AZEDRA discontinuation, associated impairments, and the Somerset site wind-down on future sales, costs, and supply.
- PYLARIFY growth, competitive position, and reimbursement terms, including CMS payment rules after its transitional pass-through status may expire.
- PNT2002 trial results and development timeline, plus the funding, milestones, and royalties potentially due for PNT2002, PNT2003, and MK-6240.
- Mo-99 and other supplier continuity, and the company’s capacity to meet demand while managing manufacturing changes and facility commitments.
- Liquidity and leverage against the $575 million note principal, revolver availability, and covenant requirements.